Top

International Journal of Clinical Oncology

Published in:

01-04-2015 | Original Article

Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab

Authors: Alexandre A. B. A. da Costa, Felipe D’Almeida Costa, Adriana R. Ribeiro, Andréia P. Guimarães, Ludmila T. Chinen, Clóvis A. P. Lopes, Vladmir C. C. de Lima

Published in: International Journal of Clinical Oncology | Issue 2/2015

Abstract

Background

Platinum-based chemotherapy associated with cetuximab is the first-line treatment for inoperable recurrence or metastatic head and neck squamous cell carcinoma (HNSCC). There is no established biomarker for cetuximab efficacy in HNSCC. The PI3K pathway is one of the most frequently altered pathways in HNSCC. Loss of phosphatase and tensin homolog (PTEN) expression occurs in up to 30 % of cases.

Methods

This was a retrospective analysis of data from 61 patients with inoperable recurrence or metastatic HNSCC treated with cetuximab. PTEN, epidermal growth factor receptor and p16 expression were analyzed by immunohistochemistry and tested for association with clinical outcomes.

Results

Median overall survival was 11.4 months and progression-free survival was 6.9 months. Low PTEN expression was present in 26.2 % of patients and identified patients with worse prognosis. p16 was positive in only 8.5 % of tumors.

Conclusions

Low PTEN expression in patients treated with cetuximab plus chemotherapy emerged as a prognostic biomarker and should be evaluated for its predictive role for cetuximab efficacy.

Available only for authorised users

Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed

Argiris A, Karamouzis MV, Raben D et al (2008) Head and neck cancer. Lancet 371:1695–1709CrossRefPubMed

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed

Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMed

Molinolo AA, Amornphimoltham P, Squarize CH et al (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45:324–334CrossRefPubMedCentralPubMed

Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967CrossRefPubMed

Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMed

Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128CrossRefPubMed

Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al (2006) Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42:109–111CrossRefPubMed

10.

Lee JW, Soung YH, Kim SY et al (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879–2882CrossRefPubMed

11.

Huang SF, Chuang WY, Chen IH et al (2009) EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. Head Neck 31:1068–1077CrossRefPubMed

12.

Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832CrossRef

13.

Chung CH, Zhang Q, Hammond EM et al (2011) Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 81:331–338CrossRefPubMedCentralPubMed

14.

Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350–7356PubMed

15.

Wheeler S, Siwak DR, Chai R et al (2012) Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18:2278–2289CrossRefPubMedCentralPubMed

16.

Pectasides E, Fountzilas G, Kountourakis P et al (2010) Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. J Clin Oncol 28(15 suppl):5538

17.

Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078–1087CrossRefPubMedCentralPubMed

18.

Licitra L, Störkel S, Kerr KM et al (2013) Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49(6):1161–1168CrossRefPubMed

19.

Morgillo F, Bareschino MA, Bianco R et al (2007) Primary and acquired resistance to anti-EGFR target drugs in cancer therapy. Differentiation 75:788–799CrossRefPubMed

20.

Matta A, Ralhan R (2009) Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 1:6CrossRefPubMedCentralPubMed

21.

Laurent-Puig P, Lievre A, Blons H (2009) Mutation and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 15:1133–1139CrossRefPubMed

22.

Cohen EEW (2011) Reply to D. Herchenhorn et al. J Clin Oncol 29:e285–e287

23.

Freudlsperger C, Burnett JR, Friedman JA et al (2011) EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 15:63–74CrossRefPubMedCentralPubMed

24.

Du L, Shen J, Weems A et al (2012) Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012:450179CrossRefPubMedCentralPubMed

25.

Pattje WJ, Schuuring E, Mastik MF et al (2010) The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br J Cancer 102:1778–1785CrossRefPubMedCentralPubMed

26.

Snietura M, Jaworska M, Mlynarczyk-Liszka J et al (2012) PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One 7:e33396CrossRefPubMedCentralPubMed

27.

Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127CrossRefPubMed

28.

Esteva FJ, Guo H, Zhang S et al (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647–1656CrossRefPubMedCentralPubMed

29.

Kokubo Y, Gemma A, Noro R et al (2005) Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92:1711–1719CrossRefPubMedCentralPubMed

30.

Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145CrossRefPubMedCentralPubMed

31.

Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622–2629CrossRefPubMed

32.

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedCentralPubMed

33.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710CrossRefPubMed

34.

Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847CrossRefPubMed

35.

El-Naggar AK, Westra WH (2012) p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 34(4):459–461CrossRefPubMed

36.

Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New YorkCrossRef

37.

Forastiere AA, Metch B, Schuller DE et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251PubMed

38.

Lui VW, Hedberg ML, Li H et al (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3:761CrossRefPubMedCentralPubMed

39.

Squarize CH, Castilho RM, Abrahao AC et al (2013) PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 15:461–471PubMedCentralPubMed

40.

Pfisterer K, Fusi A, Klinghammer K et al (2014) PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Head Neck (in press). doi:10.1002/hed.23604

41.

Lee JI, Soria JC, Hassan KA et al (2001) Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127:1441–1451CrossRefPubMed

42.

Perez EA, Dueck AC, McCullough AE et al (2013) Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 31:2115–2122CrossRefPubMedCentralPubMed

43.

Garg K, Broaddus RR, Soslow RA et al (2012) Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 31:48–56CrossRefPubMedCentralPubMed

44.

Jerusalem G, André F, Chen D et al (2013) Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trial. Eur J Cancer 49(Suppl 3):proffered papers session LBA16 p S6

45.

Yokota T (2014) Is biomarker research advancing in the era of personalized medicine for head and neck cancer? Int J Clin Oncol 19(2):211-9. doi:10.1007/s10147-013-0660-4

46.

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedCentralPubMed

47.

Vermorken JB, Psyrri A, Mesía R et al (2013) OP041: impact of human papillomavirus (HPV) and p16 status on survival and response with cisplatin plus 5-FU and cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III extreme trial. Oral Oncol 49(Suppl 1):S19–S20. ISSN 1368-8375

Title: Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
Authors: Alexandre A. B. A. da Costa
Felipe D’Almeida Costa
Adriana R. Ribeiro
Andréia P. Guimarães
Ludmila T. Chinen
Clóvis A. P. Lopes
Vladmir C. C. de Lima
Publication date: 01-04-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0707-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer

Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance

A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis

[18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer